ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer

ESMO Open. 2025 Apr;10(4):104528. doi: 10.1016/j.esmoop.2025.104528. Epub 2025 Apr 9.

Authors

T Conroy¹, M Ducreux²; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

Affiliations

¹ Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Université de Lorraine, INSERM INSPIIRE, Nancy, France.
² INSERM U1279, Université Paris-Saclay, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

Abstract

•
This ESMO Clinical Practice Guideline Express Update addresses developments in the management of metastatic pancreatic cancer.
•
It has been issued following the approval of first-line nanoliposomal irinotecan (NALIRIFOX regimen).
•
Updated first- and second-line treatment recommendations are provided.
•
An updated management algorithm for metastatic pancreatic cancer is also included.

Keywords: FOLFIRINOX; NALIRIFOX; gemcitabine; guideline; metastatic pancreatic cancer; systemic treatment.

Publication types

Practice Guideline